7.0T Magnetic Resonance Imaging Study of Parkinson's Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Parkinson's Diseases
- Sponsor
- Chinese PLA General Hospital
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- The change in motor symptoms in PD patients.
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
This clinical trial study is conducted to detect the imaging characteristics of the patients with Parkinson's diseases (PD) by 7-Tesla (7T) magnetic resonance imaging (MRI).
Detailed Description
In this study,we explored the imaging characteristics of PD. First, with the advantage of 7T, we detect the slight changes of PD with short diseases history compared with the healthy. Second, we investigate the different imaging characteristics in subtypes of PD, finding the effective neuroimaging biomarkers to distinguish different subtypes of PD. Finally, we take long time follow-up to evaluate the correlation between the imaging changes and clinical score alteration in PD.
Investigators
Xin Lou
Director and Clinical Professor
Chinese PLA General Hospital
Eligibility Criteria
Inclusion Criteria
- •the patients with PD who was diagnosed by the experienced neurologist specializing in movement disorders
Exclusion Criteria
- •the patients with brain disorders such as cerebrovascular disease, brain tumors, epilepsy, other neurodegenerative disease;
- •psychiatric disorders with impaired cognitive function;
- •contraindications to MRI.
Outcomes
Primary Outcomes
The change in motor symptoms in PD patients.
Time Frame: 5 year after the conduction of clinical trial
The patient's clinical state was evaluated according to the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) and H-Y scale. The former scale total score ranges from 0 to 199, with higher scores indicating more severe symptoms in patients. H-Y scale categorizes PD into five stages with higher stages indicate more severe symptoms. Comparison will be performed from examinations for case-control study versus for baseline and 5-year follow-up timepoints.
Secondary Outcomes
- Functional connectivity alterations between individuals with different subtypes of PD and healthy subjects.(5 year after the conduction of clinical trial)
- Structural connectivity alterations between individuals with different subtypes of PD and healthy subjects.(5 year after the conduction of clinical trial)
- Clinical variables spectrum features linking to the motor symptoms and imaging spectrum features.(5 year after the conduction of clinical trial)